Clinical trials: Sclerosis, Multiple
Amyotrophic Lateral Sclerosis
Trial of Safety, Tolerability and Efficacy of Trametinib (SNR1611) in Patients With Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to evaluate the safety, tolerability and efficacy of trametinib (SNR1611) in the treatment of amyotrophic lateral sclerosis.
- Trial name
- NCT04326283
- Testing
- Trametinib (0.5 mg), Trametinib (1 mg), Riluzole (100 mg)
- Where
- 5 sites in South Korea
- Volunteers
- 23 people
- Sponsor
- Genuv Inc.
Relapsing Remitting Multiple Sclerosis (RRMS)
Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment
The Study analyses the influence of selected factors on adherence to Betaferon treatment in patients with early multiple sclerosis (MS).
- Trial name
- BEACON (NCT00787657)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- 36 sites in Argentina, Bahrain and 34 more
- Volunteers
- 1,723 people
- Sponsor
- Bayer
Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This is a Phase 3 extension, global, multicenter study to assess the long-term safety and tolerability of tolebrutinib in adult participants (aged ≥18 years) with RMS, PPMS, or NRSPMS who were previously enrolled in the Phase 2b…
- Conditions
- Relapsing Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Progressive Relapsing Multiple Sclerosis
- Trial name
- NCT06372145
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 352 sites in United States, Argentina and 45 more
- Volunteers
- 2,500 people
- Sponsor
- Sanofi
Multiple Sclerosis
EXOPULSE Suit and Walking Ability of Patients With Multiple Sclerosis
The EXOPULSE Suit is a medical device composed of 50 electrodes capable of stimulating up to 43 major muscle groups throughout the body.
- Trial name
- EXO-MOBILITY (NCT07252895)
- Testing
- EXOPULSE Suit in Active mode
- Where
- 11 sites in France
- Volunteers
- 77 people
- Sponsor
- Otto Bock France SNC
Amyotrophic Lateral Sclerosis (ALS)
Safety Extension Study of Oral Edaravone Administered in Subjects With Amyotrophic Lateral Sclerosis (ALS)
This is a Phase 3, international, multicenter, open-label, long-term extension study. The primary objective of this study is to evaluate the long-term safety and tolerability of oral edaravone in subjects with Amyotrophic Lateral…
- Trial name
- NCT04577404
- Testing
- MT-1186
- Where
- 44 sites in United States, Canada and 4 more
- Volunteers
- 124 people
- Sponsor
- Shionogi
Renal Angiomyolipoma
Safety and Efficacy of Everolimus (Afinitor®) in Chinese Adult Patients With Angiomyolipoma Associated With Tuberous Sclerosis Complex.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
- Trial name
- NCT03525834
- Testing
- Everolimus
- Where
- 5 sites in China
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
A Study to Evaluate the Safety of Ozanimod Exposure During Pregnancy in Women With Multiple Sclerosis and Their Infants
The purpose of this retrospective observational cohort study is to assess pregnancy and infant outcomes in three groups: the first is women with multiple sclerosis (MS) who were exposed to ozanimod during pregnancy; the second is…
- Trial name
- NCT06133049
- Testing
- Ozanimod, Select DMTs other than ozanimod, No DMTs
- Where
- United States
- Volunteers
- 2,961 people
- Sponsor
- Bristol-Myers Squibb
Multiple Sclerosis
First-in-Human Study With GNbAC1 in Healthy Volunteers
The purpose of this study is to assess the safety and tolerability of single ascending doses of GNbAC1 in healthy male subjects.
- Trial name
- NCT01699555
- Testing
- GNbAC1
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- GeNeuro Innovation SAS
Tuberous Sclerosis Complex
Roll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment
The purpose of this study is to evaluate the long-term safety in patients with TSC and refractory seizures who are currently receiving everolimus treatment in the Novartis-sponsored EXIST-3 study and who are determined to be…
- Trial name
- NCT02962414
- Testing
- everolimus
- Where
- 67 sites in United States, Australia and 16 more
- Volunteers
- 206 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-remitting Multiple Sclerosis
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
The purpose of this study was to determine the dose-response curve for the MRI-based efficacy of BAF312 compared with placebo in patients with Relapsing-Remitting Multiple Sclerosis (RRMS), and to characterize its safety and…
- Trial name
- NCT00879658
- Testing
- BAF312
- Where
- 72 sites in United States, Canada and 10 more
- Volunteers
- 297 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing-Remitting Multiple Sclerosis
Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
The primary objective of this study is to evaluate the effect of symptomatic therapies on gastrointestinal-related events reported by participants with relapsing-remitting multiple sclerosis initiating therapy with BG00012…
- Trial name
- TOLERATE (NCT02125604)
- Testing
- dimethyl fumarate
- Where
- 19 sites in Germany
- Volunteers
- 214 people
- Sponsor
- Biogen
Relapsing Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary…
- Trial name
- GEMINI 1 (NCT04410978)
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 179 sites in United States, Austria and 22 more
- Volunteers
- 974 people
- Sponsor
- Sanofi
Relapsing-Remitting Multiple Sclerosis
Implementation Study of Treatment Optimization Recommendations on Relapsing-Remitting Multiple Sclerosis (RR MS) Subjects
Brief Summary: 800 RRMS Subjects currently treated with Avonex or Copaxone will be randomized to either continue on their current therapy or receive Rebif therapy. The subjects will be followed for 2 years.
- Trial name
- NCT00101959
- Testing
- Rebif
- Sponsor
- EMD Serono
Alzheimer's Disease, Multiple Sclerosis
A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery
The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies.
- Conditions
- Alzheimer's Disease, Multiple Sclerosis, Parkinson's Disease, Huntington's Disease
- Trial name
- NCT01592552
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Multiple Sclerosis
Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis
The purpose of this study is to find out if weekly Avonex works as well as three times a week Rebif in subjects with relapsing multiple sclerosis.
- Trial name
- PROOF (NCT00599274)
- Testing
- Interferon beta-1a
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 136 people
- Sponsor
- Biogen
Amyotrophic Lateral Sclerosis
Phase 3 Study of Dexpramipexole in ALS
The purpose of this study is to determine whether dexpramipexole (150 mg twice daily) is safe and effective in the treatment of Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- EMPOWER (NCT01281189)
- Testing
- Dexpramipexole
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 942 people
- Sponsor
- Knopp Biosciences
Multiple Sclerosis
EPID Multiple Sclerosis Pregnancy Study
Multiple Sclerosis (MS) is the most common chronic neurologic disability in young adult females in their childbearing ages. Little evidence is available regarding the association between exposure to IFN-beta (β) products and…
- Trial name
- NCT02749396
- Testing
- Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG, Extavia (interferon beta-1b), Novartis Pharma AG, Rebif (interferon beta-1a), Merck Serono Europe Ltd
- Where
- Finland
- Volunteers
- 2,089 people, healthy volunteers welcome
- Sponsor
- Bayer
Multiple Sclerosis
The Effects of Tysabri Treatment on Vaccination Response and Lymphocyte Subsets in Subjects With Relapsing Forms of Multiple Sclerosis
The primary objectives of this study were: to evaluate the effect of Tysabri® (natalizumab) on antibody responses after immunization with a neoantigen (keyhole limpet hemocyanin [KLH]) and a recall antigen (tetanus toxoid [Td])…
- Trial name
- NCT00536120
- Testing
- BG00002 (natalizumab), keyhole limpet hemocyanin (KLH), tetanus diphtheria toxoid vaccine (Td)
- Where
- 10 sites in United States
- Volunteers
- 60 people
- Sponsor
- Biogen
Systematic Sclerosis, Digital Ulcer
Bosentan Treatment of Digital Ulcers Related to Systemic Sclerosis
GRegistry is a significant collection of data and information on the clinical practice of systemic scleroderma finger ulcers. The GRegistry study is a nationwide (Greece) prospective study recording, which includes consecutive…
- Conditions
- Systematic Sclerosis, Digital Ulcer, Scleroderma
- Trial name
- GRegistry SCDU (NCT02798055)
- Testing
- Bosentan group
- Where
- Greece
- Volunteers
- 148 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate the Effects of Ocrelizumab on Immune Responses In Participants With Relapsing Forms of Multiple Sclerosis
This multicenter, randomized, open-label study will evaluate the immune response to vaccines (tetanus toxoid [TT]-containing adsorbed vaccine, 23-valent pneumococcal polysaccharide vaccine [23-PPV] either unboosted or boosted…
- Trial name
- NCT02545868
- Testing
- 23-PPV, 13-PCV Booster, Influenza Vaccine
- Where
- 22 sites in United States, Canada
- Volunteers
- 102 people
- Sponsor
- Hoffmann-La Roche